SAN FRANCISCO — The J.P. Morgan Healthcare Conference isn’t just a venue for companies in the industry to outline their plans for the year or tamp down questions about their finances. The week is also a time for many venture capitalists to meet with startups or other investors to make plans for the year.
So, what are their plans for new investments? Well, most venture capitalists are loath to share details on their new bets before all of the paperwork is signed. Multiple times during my meetings with investors, I found them glancing over at public relations people shaking their heads to quietly signal no, don’t answer that question. Or, the investors blamed their lawyers: “I’d love to tell you, but our attorneys would kill me.”
That being said, clear themes often emerge during JPM. I sat down with a half-dozen investors over the last week to discuss what disease areas or drug mechanisms they’re most interested in. Here’s what they told me:
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
